Table 1.
Clinical and biologic characteristics of chronic lymphocytic leukemia population, cohort, and CLL-PI class of risk patients
| Characteristics | Population (n = 406) | Cohort (n = 173) | t/X2 | P | Low risk* (n = 22) | Intermediate low risk* (n = 54) | Intermediate high risk* (n = 43) | High risk* (n = 54) | F/X2 | P |
|---|---|---|---|---|---|---|---|---|---|---|
| Age at diagnosis (years), mean (range) | 58 (26–85) | 56 (26–85) | 1.043 | 1.0 | 61 (47–71) | 54 (36–72) | 57 (38–85) | 53 (26–80) | 3.639 | 0.297 |
| Gender, n (%) | ||||||||||
| Male | 266 (66) | 120 (69) | 0.700 | 0.403 | 13 (59) | 39 (72) | 34 (79) | 34 (63) | 4.160 | 0.245 |
| Female | 140 (34) | 53 (31) | 9 (41) | 15 (28) | 9 (21) | 20 (37) | ||||
| Rai, n (%) | ||||||||||
| Low risk (0) | 60 (15) | 27 (16) | 0.087 | 0.958 | 22 (100) | 0 | 4 (9) | 1 (2) | 219.927 | <0.001 |
| Intermediate risk (I–II) | 211 (52) | 88 (51) | 0 | 54 (56) | 0 | 34 (63) | ||||
| High risk (III–IV) | 135 (33) | 58 (34) | 0 | 0 | 39 (91) | 19 (35) | ||||
| Binet, n (%) | ||||||||||
| A | 157 (40) | 66 (39) | 1.389 | 0.499 | 22 (100) | 29 (56) | 4 (9) | 11 (21) | 144.437 | <0.001 |
| B | 104 (27) | 53 (31) | 0 | 23 (44) | 1 (2) | 29 (55) | ||||
| C | 131 (33) | 51 (30) | 0 | 0 | 38 (88) | 13 (24) | ||||
| Elevated LDH, n (%) | ||||||||||
| Yes | 91 (26) | 37 (25) | 0.063 | 0.802 | 2 (12) | 10 (22) | 7 (19) | 18 (35) | 5.515 | 0.138 |
| No | 265 (74) | 114 (75) | 15 (88) | 36 (78) | 30 (81) | 33 (65) | ||||
| Elevated β2-MG, n (%) | ||||||||||
| Yes | 99 (42) | 48 (43) | 0.001 | 0.976 | 3 (27) | 7 (20) | 18 (60) | 20 (54) | 14.077 | 0.003 |
| No | 135 (58) | 65 (58) | 8 (73) | 28 (80) | 12 (40) | 17 (46) | ||||
| B symptoms, n (%) | ||||||||||
| Yes | 90 (28) | 35 (23) | 0.969 | 0.325 | 1 (6) | 6 (13) | 10 (27) | 18 (35) | 9.770 | 0.021 |
| No | 236 (72) | 115 (77) | 16 (94) | 39 (87) | 27 (73) | 33 (65) | ||||
| Hepatomegaly, n (%) | ||||||||||
| Yes | 23 (7) | 10 (7) | 0.000 | 0.984 | 1 (6) | 2 (5) | 3 (8) | 4 (9) | 0.639 | 0.887 |
| No | 313 (93) | 135 (93) | 15 (94) | 42 (95) | 35 (92) | 43 (91) | ||||
| Splenomegaly, n (%) | ||||||||||
| Yes | 149 (43) | 63 (43) | 0.003 | 0.953 | 1 (6) | 20 (45) | 20 (53) | 22 (46) | 10.510 | 0.015 |
| No | 194 (57) | 83 (57) | 15 (94) | 24 (55) | 18 (47) | 26 (54) | ||||
| FISH, n (%) | ||||||||||
| 13q− | 102 (35) | 42 (32) | 1.577 | 0.904 | 11 (69) | 16 (43) | 14 (42) | 1 (2) | 54.676 | <0.001 |
| Normal | 75 (26) | 34 (26) | 4 (25) | 8 (22) | 7 (21) | 15 (33) | ||||
| +12 | 43 (15) | 21 (16) | 0 | 9 (24) | 6 (18) | 6 (13) | ||||
| 11q− | 34 (12) | 19 (14) | 1 (6) | 4 (11) | 5 (15) | 9 (20) | ||||
| 17p− | 39 (13) | 16 (12) | 0 | 0 | 1 (3) | 15 (33) | ||||
| IGHV, n (%) | ||||||||||
| M-IGHV | 131 (71) | 120 (69) | 0.089 | 0.765 | 22 (100) | 54 (100) | 40 (93) | 4 (7) | 142.439 | <0.001 |
| U-IGHV | 54 (29) | 53 (31) | 0 | 0 | 3 (7) | 50 (93) |
*This analysis was performed on cohort of 173 patients. LDH: Lactate dehydrogenase; β2-MG: β2-microglobulin; FISH: Fluorescence in situ hybridization; CLL-PI: Chronic lymphocytic leukemia prognostic index; IGHV: Immunoglobulin heavy chain variable region; M: Mutated; U: Unmutated.